RT3 — Triple Receptor Agonist Research Peptide
RT3 is a next-generation research peptide engineered to simultaneously engage three metabolic receptor targets: GLP-1, GIP, and glucagon receptors. This triple agonist mechanism represents a significant advancement over single- and dual-receptor compounds in preclinical metabolic research.
Mechanism of Action
RT3 activates glucagon-like peptide-1 (GLP-1) receptors to potentiate glucose-dependent insulin secretion, glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance incretin signaling, and glucagon receptors to promote energy expenditure and lipid oxidation. The combined activation of all three pathways creates a synergistic metabolic effect studied extensively in preclinical models of obesity and insulin resistance.
Research Applications
- Metabolic pathway modulation and energy homeostasis
- Insulin sensitivity and glucose regulation studies
- Appetite signaling and food intake research
- Body composition and lipid metabolism investigations
- Comparative studies with single- and dual-receptor agonists
Product Specifications
- Quantity: 10mg per vial
- Purity: ≥99% (HPLC verified)
- Form: Lyophilized powder
- Storage: Refrigerate after reconstitution
- Testing: USA lab tested, COA available
For research purposes only. Not for human use or consumption.
133 reviews for RT3 (Reta)